Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01235221 |
|
Recruitment Status :
Completed
First Posted : November 5, 2010
Last Update Posted : July 4, 2014
|
Sponsor:
Biogen
Collaborator:
Acorda Therapeutics
Information provided by (Responsible Party):
Biogen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | June 2012 |
| Actual Study Completion Date : | June 2012 |